Breast Biopsy Devices Market By Biopsy Type (Fine Needle Aspiration Biopsy (FNAB), Core Needle Biopsy (CNB), Vacuum Assisted Breast Biopsy (VABB), Incisional And Excisional Breast Biopsy) By Products (Needle Based Biopsy Guns, Biopsy Guidance Systems, Biopsy Forceps, Biopsy Needles, Others) By Guidance Modality (Stereotactic X-ray Guided Biopsy, Ultrasound Guided Biopsy, Mri Guided Biopsy, Without Imaging Guidance Biopsy) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

A breast biopsy is the extraction of a tissue sample from the breast for examination and diagnosis. Due to the advantage of least disfigurement and pain, physicians are increasingly performing minimally invasive biopsy procedures.

Therefore, the prime factors that support the market growth of breast biopsy devices are:

• The increasing incidence of breast cancer.
• Growing awareness about cancer screening programs.
• Advancing preference for minimally invasive procedures and dedicated systems. 

Perpetual technological advances in diagnostics and treatment methods for breast cancer have facilitated the introduction of minimally invasive procedures, thereby improving the treatment outcome rate. Breast cancer is among the most common cancer types in women worldwide, and growing awareness has facilitated high demand for advanced diagnostic techniques. However, the risk of infections and affordability issues may hold back the growth of this market.

Vacuum Assisted Breast Biopsy Technology to Spearhead the Global Market

Conventionally, open surgical breast biopsies were the gold standard for sample extraction. However, with the advent of fine needle aspiration, the clinical scenario underwent a transition, and minimally invasive procedures witnessed significant growth in demand. However, drawbacks of fine needle aspiration procedures such as compromised accuracy in determining PR, ER, and Her-2 status, high risk of negative results, and absence of standard interpretation guidelines led to the replacement of this technique by further advanced procedures such as vacuum-assisted breast biopsy and core needle biopsy. Currently, the global breast biopsy devices market is dominated by widespread acceptance of vacuum-assisted breast biopsy procedures, which conveniently overcomes conventional methods' drawbacks.

Uptake of Guidance Systems to Remain Steady through the Forecast Period

In 2017, the global breast biopsy devices market witnessed biopsy guidance systems having the largest revenue share. The segment will continue to dominate the overall market through the forecast period. Long equipment life, established clinical evidence on efficacy and moderate equipment cost are the major factors that are contributing to the prime position of the biopsy guidance systems segment. However, the share of this segment will be cannibalized by the growing uptake of biopsy needles during the forecast period. Faster uptake of these products and growing demand for disposable needles in both developed and developing markets contribute to the faster growth rate of this segment.

The upswing in Adoption of MRI Guidance Modality to Boost the Market Growth

Currently, stereotactic x-ray-guided biopsy systems enjoy the dominance in the overall breast biopsy devices market. This modality, since its introduction, has gradually replaced conventional open surgical biopsies. This modality is often viewed as cost-effective and has been adopted worldwide. However, the dominance of stereotactic x-ray-guided biopsy is challenged by the growing uptake of MRI-guided biopsy. An MRI-guided biopsy is widely adopted in developed markets of North America and Europe because of better precision and greater awareness among paints and physicians.

Asia Pacific Set to Cannibalize on Market Shares of North America and Europe

Breast biopsy devices find wide usage in cancer diagnosis and disease progress and treatment outcome monitoring. North America is the largest regional market for breast biopsy devices due to the complete replacement of open surgical biopsy procedures with minimally invasive counterparts. Additionally, better reimbursements for the latest and advanced biopsy modalities are also attributed to the dominance of the North American market. However, the North American market will lose significant market share to the rapidly advancing Asia Pacific market during the forecast period. The fast evolution of healthcare infrastructure, growing replacement of stereotactic X-ray biopsy systems with MRI-guided systems, and growing base of breast cancer patients are the key drivers of the Asia Pacific breast cancer devices market.

Additionally, the swift progress of medical tourism in the region will open further market penetration opportunities for manufacturers.

By Biopsy Type (2016–2026; US$ Mn)

• Fine Needle Aspiration Biopsy (FNAB)
• Core Needle Biopsy (CNB)
• Vacuum Assisted Breast Biopsy (VABB)
• Incisional and Excisional Breast Biopsy

By Product (2016–2026; US$ Mn)

• Needle-Based Biopsy Guns
• Biopsy Guidance Systems
• Biopsy Forceps
• Biopsy Needles
• Others (Curettes, Punches, Markers)

By Guidance Modality (2016–2026; US$ Mn)

• Stereotactic X-ray Guided Biopsy
• Ultrasound Guided Biopsy
• MRI Guided Biopsy
• Without Imaging Guidance Biopsy

The market dynamics in the breast biopsy devices industry are studied in the market overview section of the report, where the market drivers, challenges, and prospects in the market are scrutinized. This section also includes a graphical presentation of the competitive landscape in the global breast biopsy devices market. Major players operating in the global breast biopsy devices market are studied based on their business overview, product portfolio, financial information, and key developments. Hologic, Becton, Dickinson and Company, C.R. Bard, Inc., Mammotome (Devicor Medical Products, Inc.), Aurora Imaging Technology, Inc., and Planmed OY are the prime market players considered in this section.

Key questions answered in this report

• How is the breast biopsy devices industry currently sands in the global market?
• What is the global breast biopsy devices market's future roadmap from 2018 to 2026?
• What are the key drivers and challenges prevalent in the market?
• How are the current market movements opening new opportunities in the global market?
• What key growth initiatives or steps undertaken by the major market players for sustenance or dominance?
• Which guidance modality will enjoy prominence in the global breast biopsy devices market within the forecast period?
• How will the Asia Pacific market fare within the forecast period?
• In what terms will the Asia Pacific challenge the dominance of the North American market?
• What are the positions held by key players in the global breast biopsy devices market?

Frequently Asked Questions